We are exploring the best sequence of EGFR-inhibitors for patients with EGFR-mutated lung cancer. The study also examines treatment effects, side effects, and quality of life.
Health conditions and diseases that the clinical trial is designed to study and treat.
EGFR-mutated non-small cell lung cancer (NSCLC) is a type of lung cancer characterized by mutations in the EGFR gene, which can affect treatment options. This condition is not typically curable but can be managed with targeted therapies like EGFR inhibitors.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.